In this episode, UROONCO RCC chief editor Dr. Carmen Mir talks to Assoc. Prof. Pedro Barata from Case Western Reserve University, Ohio (US). They discuss the results of the ctDNA analysis in participants with renal cell carcinoma (RCC) treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial and the potential impact of these results for clinical practice.
For more updates on kidney cancer, please visit our educational platform UROONCO RCC.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
Podden och tillhörande omslagsbild på den här sidan tillhör
European Association of Urology. Innehållet i podden är skapat av European Association of Urology och inte av,
eller tillsammans med, Poddtoppen.